We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Molecular Urine Test Validated for Schistosomiasis

By LabMedica International staff writers
Posted on 16 Jan 2012
Urogenital schistosomiasis in chronically infected adults can be diagnosed by the detection of parasite specific DNA fragments. More...


The sensitivity and specificity of three tests have been evaluated for the viable infection of Schistosoma haematobium in the urogenital tract, which included a polymerase chain reaction hematuria, and the presence of parasite eggs.

A team of collaborating scientists under the auspices of those at Johns Hopkins University (Baltimore, MD, USA) collected over 400 urine samples from adult volunteers in an endemic area in Western Nigeria. These were assessed for hematuria then filtered in the field, the filter papers dried and later examined for eggs and DNA. The results were stratified according to sex and age and subjected to Latent Class analysis.

The DNA was precipitated and concentrated using the Qiagen QIAmp (Qiagen; Germantown, MD, USA) mini- kit. The extracted DNA was used for PCR amplification. The primers were designed to amplify the 121 bp tandem repeat restriction endonuclease from Deinococcus radiophilus (Dra-1) sequence of S. haematobium. Each urine sample was tested with a Hemastix (Bayer; Elkhart, IN, USA) test strip to detect hematuria.

The PCR test indicating the presence of Dra1 DNA fragments in males was 100% for both sensitivity and specificity. This exceeded hematuria with a sensitivity and specificity of 87.6% and 34.7%, respectively, while the detection of eggs, the sensitivity was 70.1% and specificity was 100%. There were similar results for the females except the specificity of the hematuria was 77.0%.

To test the effect of parasite clearance on the persistence of Dra1 fragment, a group of 55 persons who were positive either for presence of parasites eggs and/or DNA in the urine, were followed up two weeks after treatment with praziquantel. Of these 26 (47.3%) were positive for parasite eggs and 42 (76.4%) were positive for DNA. None of these people were positive for eggs or parasite specific DNA in the follow up.

The authors concluded that the molecular test is extremely promising for the diagnosis of urogenital schistosomiasis and should also be useful in field studies as it will be able to reveal infections in people frequently presumed to be uninfected. The PCR test indicated the presence of schistosomes in 10.7% of adults who did not pass eggs in urine specimens. The study was published online on January 3, 2012, in the journal Public Library of Science Neglected tropical Diseases (PLoSNTD).

Related Links:

Johns Hopkins University
Qiagen
Bayer



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.